Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inhaled Nitric Oxide Clear all
Completed Phase 2 Interventional

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

NCT01457781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
16 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 1 Interventional

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

NCT00023296
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Nitric Oxide, INO Pulse - NO Delivery System
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574
View directory record Official record
Conditions
Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 26, 2026, 1:49 AM EDT
Recruiting No phase listed Observational

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

NCT06690801
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
0 Years to 21 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism

NCT00848731
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
nitric oxide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

NCT01529502
View directory record Official record
Conditions
Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions
Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

NCT00626028
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions
Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

NCT00931632
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Days to 14 Days
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation

NCT02305550
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
electrical pulsed plasma discharge synthesis of nitric oxide
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Inhaled Nitric Oxide and Neuroprotection in Premature Infants

NCT00515281
View directory record Official record
Conditions
Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia
Interventions
inhaled nitric oxide, oxygen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
2 Hours to 72 Hours
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 4 Interventional

Inhaled Nitric Oxide by Oxygen Hood in Neonates

NCT00732537
View directory record Official record
Conditions
Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions
inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 1 Week
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
INOpulse, Placebo
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 4 Interventional

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

NCT04231084
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Vasodilator testing (Inhaled Nitric Oxide), Vasodilator testing (Inhaled Epoprostenol)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises

NCT00094887
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Oakland, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 26, 2026, 1:49 AM EDT
Not yet recruiting Not applicable Interventional

Inhaled Nitric Oxide in Severe Obesity

NCT06675435
View directory record Official record
Conditions
Obesity, Respiratory Insufficiency, Hypoxemic Respiratory Failure, Nitric Oxide
Interventions
Nitric oxide
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional Results available

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

NCT01467076
View directory record Official record
Conditions
Prematurity, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
Interventions
Aerosolized Normal Saline, Inhaled PGE1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation

NCT00582010
View directory record Official record
Conditions
Reperfusion Injury, Liver Injury
Interventions
inhaled nitric oxide, nitrogen gas
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 3 Interventional

Inhaled Nitric Oxide Study for Respiratory Failure in Newborns

NCT00005776
View directory record Official record
Conditions
Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration, Respiratory Distress Syndrome, Newborn, Respiratory Insufficiency
Interventions
Inhaled nitric oxide, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 14 Days
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1998
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 26, 2026, 1:49 AM EDT
Completed No phase listed Observational

Neonatal Intensive Care (NICU) Course and Hospital Outcome of Infants With BPD Treated Using Inhaled Nitric Oxide

NCT00757146
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 28 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

NCT02734953
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 26, 2026, 1:49 AM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching Placebo, ICS/LABA
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

NCT00867477
View directory record Official record
Conditions
Gastrointestinal Disease, Esophageal Cancer, Lung Cancer
Interventions
Breathing Test, Respiratory Symptoms Questionnaire, Pet Scan
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Sep 26, 2026, 1:49 AM EDT
Recruiting Phase 4 Interventional

De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia

NCT05213676
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
Inhaled Nitric Oxide (iNO) use, De-implementation of Inhaled Nitric Oxide (iNO) use
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
0 Months to 1 Month
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 26, 2026, 1:49 AM EDT